Direct Effect of Bevacizumab on Glioblastoma Cell Lines In Vitro

NeuroMolecular Medicine

Volumn 16, Issue 4, 2014, Pages 752-771

  Simon, Thomas ^a,b   Coquerel, Bérénice ^a,b   Petit, Alexandre ^a,b   Kassim, Yusra ^a,b   Demange, Elise ^a,b,c   Le Cerf, Didier ^d,e   Perrot, Valérie ^a,b   Vannier, Jean Pierre ^a,b  

^a UNIVERSITÉ DE ROUEN   (France)

^b NORMANDIE UNIVERSITÉ   (France)

^c Celenys SAS   (France)

^d UNIVERSITÉ DE ROUEN   (France)

^e Normandie Université   (France)

Author keywords

Anti angiogenic therapies; Autocrine loop; Brain extracellular matrix; Glioblastoma; VEGF A

Indexed keywords

AKT1 PROTEIN, HUMAN; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; HYALURONIC ACID; HYDROGEL; INDOLE DERIVATIVE; MONOCLONAL ANTIBODY; PLACENTA PROTEIN; PLACENTAL GROWTH FACTOR; PROTEIN KINASE B; PROTEIN KINASE INHIBITOR; PYRROLE DERIVATIVE; SUNITINIB; TUMOR PROTEIN; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2, HUMAN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VEGFA PROTEIN, HUMAN;

ANTAGONISTS AND INHIBITORS; AUTOCRINE EFFECT; BIOSYNTHESIS; BRAIN TUMOR; CALCIUM SIGNALING; CELL DIVISION; CELL MOTION; CULTURE TECHNIQUE; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; GLIOBLASTOMA; HUMAN; HYDROGEL; PATHOLOGY; PHYSIOLOGY; SECRETION (PROCESS); SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR INVASION;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; AUTOCRINE COMMUNICATION; BRAIN NEOPLASMS; CALCIUM SIGNALING; CELL CULTURE TECHNIQUES; CELL DIVISION; CELL LINE, TUMOR; CELL MOVEMENT; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; HYALURONIC ACID; HYDROGELS; INDOLES; MAP KINASE SIGNALING SYSTEM; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; PREGNANCY PROTEINS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; PYRROLES; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84929625512     PISSN: 15351084     EISSN: 15591174     Source Type: Journal    
DOI: 10.1007/s12017-014-8324-8     Document Type: Article

References (54)

1. Cao, Y., Zhong, W., & Sun, Y. (2009). Improvement of antiangiogenic cancer therapy by understanding the mechanisms of angiogenic factor interplay and drug resistance. Seminars in Cancer Biology,19(5), 338–343. doi:10.1016/j.semcancer.2009.05.001.
2. Charles, N. A., Holland, E. C., Gilbertson, R., Glass, R., & Kettenmann, H. (2012). The brain tumor microenvironment. Glia,60(3), 502–514.
3. Chauzy, C., Delpech, B., Olivier, A., Bastard, C., Girard, N., Courel, M. N., Creissard, P. (1992). Establishment and characterisation of a human glioma cell line. European journal of cancer (Oxford, England: 1990), 28A(6–7), 1129–1134.
4. Coquerel, B., Poyer, F., Torossian, F., Dulong, V., Bellon, G., Dubus, I., et al. (2009). Elastin-derived peptides: Matrikines critical for glioblastoma cell aggressiveness in a 3-D system. Glia,57(16), 1716–1726. doi:10.1002/glia.20884.
5. David, L., Dulong, V., Le Cerf, D., Cazin, L., Lamacz, M., & Vannier, J.-P. (2008). Hyaluronan hydrogel: An appropriate three-dimensional model for evaluation of anticancer drug sensitivity. Acta Biomaterialia,4(2), 256–263. doi:10.1016/j.actbio.2007.08.012.
6. David, L., Dulong, V., Le Cerf, D., Chauzy, C., Norris, V., Delpech, B., et al. (2004). Reticulated hyaluronan hydrogels: A model for examining cancer cell invasion in 3D. Matrix Biology: Journal of the International Society for Matrix Biology,23(3), 183–193. doi:10.1016/j.matbio.2004.05.005.
7. De Groot, J. F., Fuller, G., Kumar, A. J., Piao, Y., Eterovic, K., Ji, Y., et al. (2010). Tumor invasion after treatment of glioblastoma with bevacizumab: Radiographic and pathologic correlation in humans and mice. Neuro-oncology,12(3), 233–242. doi:10.1093/neuonc/nop027.
8. DeAngelis, L. M. (2001). Brain tumors. The New England journal of medicine,344(2), 114–123. doi:10.1056/NEJM200101113440207.
9. Ellis, L. M., & Hicklin, D. J. (2008). Pathways mediating resistance to vascular endothelial growth factor-targeted therapy. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research,14(20), 6371–6375. doi:10.1158/1078-0432.CCR-07-5287.
10. Fan, F., Samuel, S., Gaur, P., Lu, J., Dallas, N. A., Xia, L., et al. (2011). Chronic exposure of colorectal cancer cells to bevacizumab promotes compensatory pathways that mediate tumour cell migration. British Journal of Cancer,104(8), 1270–1277. doi:10.1038/bjc.2011.81.
11. Ferrara, N. (2009). VEGF-A: A critical regulator of blood vessel growth. European Cytokine Network,20(4), 158–163. doi:10.1684/ecn.2009.0170.
12. Ferrara, N. (2010). Binding to the extracellular matrix and proteolytic processing: Two key mechanisms regulating vascular endothelial growth factor action. Molecular Biology of the Cell,21(5), 687–690. doi:10.1091/mbc.E09-07-0590.
13. Ferrara, N., Hillan, K. J., & Novotny, W. (2005). Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochemical and Biophysical Research Communications,333(2), 328–335. doi:10.1016/j.bbrc.2005.05.132.
14. Fischer, C., Jonckx, B., Mazzone, M., Zacchigna, S., Loges, S., Pattarini, L., et al. (2007). Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell,131(3), 463–475. doi:10.1016/j.cell.2007.08.038.
15. Folkman, J. (1971). Tumor angiogenesis: Therapeutic implications. The New England Journal of Medicine,285(21), 1182–1186. doi:10.1056/NEJM197111182852108.
16. Friedman, H. S., Prados, M. D., Wen, P. Y., Mikkelsen, T., Schiff, D., Abrey, L. E., et al. (2009). Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology,27(28), 4733–4740. doi:10.1200/JCO.2008.19.8721.
17. Galas, L., Garnier, M., & Lamacz, M. (2000). Calcium waves in frog melanotrophs are generated by intracellular inactivation of TTX-sensitive membrane Na+ channel. Molecular and Cellular Endocrinology,170(1–2), 197–209.
18. Grau, S., Thorsteinsdottir, J., von Baumgarten, L., Winkler, F., Tonn, J.-C., & Schichor, C. (2011). Bevacizumab can induce reactivity to VEGF-C and -D in human brain and tumour derived endothelial cells. Journal of Neuro-oncology,104(1), 103–112. doi:10.1007/s11060-010-0480-6.
19. Hoelzinger, D. B., Demuth, T., & Berens, M. E. (2007). Autocrine factors that sustain glioma invasion and paracrine biology in the brain microenvironment. Journal of the National Cancer Institute,99(21), 1583–1593. doi:10.1093/jnci/djm187.
20. Hong, X., Jiang, F., Kalkanis, S. N., Zhang, Z. G., Zhang, X.-P., DeCarvalho, A. C., et al. (2006). SDF-1 and CXCR4 are up-regulated by VEGF and contribute to glioma cell invasion. Cancer Letters,236(1), 39–45. doi:10.1016/j.canlet.2005.05.011.
21. Jackson, A. P., Timmerman, M. P., Bagshaw, C. R., & Ashley, C. C. (1987). The kinetics of calcium binding to fura-2 and indo-1. FEBS Letters,216(1), 35–39.
22. Keunen, O., Johansson, M., Oudin, A., Sanzey, M., Rahim, S. A. A., Fack, F., et al. (2011). Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proceedings of the National Academy of Sciences of the United States of America,108(9), 3749–3754. doi:10.1073/pnas.1014480108.
23. Knizetova, P., Darling, J. L., & Bartek, J. (2008a). Vascular endothelial growth factor in astroglioma stem cell biology and response to therapy. Journal of Cellular and Molecular Medicine,12(1), 111–125. doi:10.1111/j.1582-4934.2007.00153.x.
24. Knizetova, P., Ehrmann, J., Hlobilkova, A., Vancova, I., Kalita, O., Kolar, Z., & Bartek, J. (2008b). Autocrine regulation of glioblastoma cell cycle progression, viability and radioresistance through the VEGF-VEGFR2 (KDR) interplay. Cell cycle (Georgetown, Tex.), 7(16), 2553–2561.
25. Kwiatkowska, A., & Symons, M. (2013). Signaling determinants of glioma cell invasion. Advances in Experimental Medicine and Biology,986, 121–141. doi:10.1007/978-94-007-4719-7_7.
26. Lee, S., Jilani, S. M., Nikolova, G. V., Carpizo, D., & Iruela-Arispe, M. L. (2005). Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. The Journal of Cell Biology,169(4), 681–691. doi:10.1083/jcb.200409115.
27. Lee, J., Lee, J., Yu, H., Choi, K., & Choi, C. (2011). Differential dependency of human cancer cells on vascular endothelial growth factor-mediated autocrine growth and survival. Cancer Letters,309(2), 145–150. doi:10.1016/j.canlet.2011.05.026.
28. Lucio-Eterovic, A. K., Piao, Y., & de Groot, J. F. (2009). Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research,15(14), 4589–4599. doi:10.1158/1078-0432.CCR-09-0575.
29. Mahesparan, R., Read, T.-A., Lund-Johansen, M., Skaftnesmo, K. O., Bjerkvig, R., & Engebraaten, O. (2003). Expression of extracellular matrix components in a highly infiltrative in vivo glioma model. Acta Neuropathologica,105(1), 49–57. doi:10.1007/s00401-002-0610-0.
30. Masood, R., Cai, J., Zheng, T., Smith, D. L., Hinton, D. R., & Gill, P. S. (2001). Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors. Blood,98(6), 1904–1913.
31. Mellinghoff, I. K., Lassman, A. B., & Wen, P. Y. (2011). Signal transduction inhibitors and antiangiogenic therapies for malignant glioma. Glia,59(8), 1205–1212. doi:10.1002/glia.21137.
32. Miletic, H., Niclou, S. P., Johansson, M., & Bjerkvig, R. (2009). Anti-VEGF therapies for malignant glioma: Treatment effects and escape mechanisms. Expert Opinion on Therapeutic Targets,13(4), 455–468. doi:10.1517/14728220902806444.
33. Moreno Garcia, V., Basu, B., Molife, L. R., & Kaye, S. B. (2012). Combining antiangiogenics to overcome resistance: Rationale and clinical experience. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research,18(14), 3750–3761. doi:10.1158/1078-0432.CCR-11-1275.
34. Nakada, M., Nakada, S., Demuth, T., Tran, N. L., Hoelzinger, D. B., & Berens, M. E. (2007). Molecular targets of glioma invasion. Cellular and Molecular Life Sciences: CMLS,64(4), 458–478. doi:10.1007/s00018-007-6342-5.
35. Olsson, A.-K., Dimberg, A., Kreuger, J., & Claesson-Welsh, L. (2006). VEGF receptor signalling: In control of vascular function. Nature Reviews Molecular Cell Biology,7(5), 359–371. doi:10.1038/nrm1911.
36. Plate, K. H., Scholz, A., & Dumont, D. J. (2012). Tumor angiogenesis and anti-angiogenic therapy in malignant gliomas revisited. Acta Neuropathologica,124(6), 763–775. doi:10.1007/s00401-012-1066-5.
37. Pollo, B. (2012). Pathological classification of brain tumors. The Quarterly Journal of Nuclear Medicine and Molecular Imaging: Official Publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of Radiopharmaceutical Chemistry and Biology,56(2), 103–111.
38. Rahman, R., Smith, S., Rahman, C., & Grundy, R. (2010). Antiangiogenic therapy and mechanisms of tumor resistance in malignant glioma. Journal of Oncology,2010, 251231. doi:10.1155/2010/251231.
39. Red-Horse, K., Crawford, Y., Shojaei, F., & Ferrara, N. (2007). Endothelium-microenvironment interactions in the developing embryo and in the adult. Developmental Cell,12(2), 181–194. doi:10.1016/j.devcel.2007.01.013.
40. Stupp, R., Hegi, M. E., Mason, W. P., van den Bent, M. J., Taphoorn, M. J. B., Janzer, R. C., et al. (2009). Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. The Lancet Oncology,10(5), 459–466. doi:10.1016/S1470-2045(09)70025-7.
41. Tabatabai, G., Weller, M., Nabors, B., Picard, M., Reardon, D., Mikkelsen, T., et al. (2010). Targeting integrins in malignant glioma. Targeted Oncology,5(3), 175–181. doi:10.1007/s11523-010-0156-3.
42. Takano, S., Mashiko, R., Osuka, S., Ishikawa, E., Ohneda, O., & Matsumura, A. (2010). Detection of failure of bevacizumab treatment for malignant glioma based on urinary matrix metalloproteinase activity. Brain Tumor Pathology,27(2), 89–94. doi:10.1007/s10014-010-0271-y.
43. Tate, M. C., & Aghi, M. K. (2009). Biology of angiogenesis and invasion in glioma. Neurotherapeutics: The Journal of the American Society for Experimental NeuroTherapeutics,6(3), 447–457. doi:10.1016/j.nurt.2009.04.001.
44. Thompson, E. M., Frenkel, E. P., & Neuwelt, E. A. (2011). The paradoxical effect of bevacizumab in the therapy of malignant gliomas. Neurology,76(1), 87–93. doi:10.1212/WNL.0b013e318204a3af.
45. Tuettenberg, J., Friedel, C., & Vajkoczy, P. (2006). Angiogenesis in malignant glioma: A target for antitumor therapy? Critical Reviews in Oncology/Hematology,59(3), 181–193. doi:10.1016/j.critrevonc.2006.01.004.
46. Videira, P. A., Piteira, A. R., Cabral, M. G., Martins, C., Correia, M., Severino, P., et al. (2011). Effects of bevacizumab on autocrine VEGF stimulation in bladder cancer cell lines. Urologia Internationalis,86(1), 95–101. doi:10.1159/000321905.
47. Vredenburgh, J. J., Desjardins, A., Herndon, J. E, 2nd, Dowell, J. M., Reardon, D. A., Quinn, J. A., et al. (2007). Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research,13(4), 1253–1259. doi:10.1158/1078-0432.CCR-06-2309.
48. Wade, A., Robinson, A. E., Engler, J. R., Petritsch, C., James, C. D., & Phillips, J. J. (2013). Proteoglycans and their roles in brain cancer. The FEBS Journal,280(10), 2399–2417. doi:10.1111/febs.12109.
49. Watkins, S., & Sontheimer, H. (2012). Unique biology of gliomas: Challenges and opportunities. Trends in Neurosciences,35(9), 546–556. doi:10.1016/j.tins.2012.05.001.
50. Wen, P. Y., & Kesari, S. (2008). Malignant gliomas in adults. The New England Journal of Medicine,359(5), 492–507. doi:10.1056/NEJMra0708126.
51. Xu, T., Chen, J., Lu, Y., & Wolff, J. E. (2010). Effects of bevacizumab plus irinotecan on response and survival in patients with recurrent malignant glioma: A systematic review and survival-gain analysis. BMC Cancer,10, 252. doi:10.1186/1471-2407-10-252.
52. Xu, L., Duda, D. G., di Tomaso, E., Ancukiewicz, M., Chung, D. C., Lauwers, G. Y., et al. (2009). Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer. Cancer Research,69(20), 7905–7910. doi:10.1158/0008-5472.CAN-09-2099.
53. Yamagishi, N., Teshima-Kondo, S., Masuda, K., Nishida, K., Kuwano, Y., Dang, D. T., et al. (2013). Chronic inhibition of tumor cell-derived VEGF enhances the malignant phenotype of colorectal cancer cells. BMC Cancer,13(1), 229. doi:10.1186/1471-2407-13-229.
54. Zimmermann, D. R., & Dours-Zimmermann, M. T. (2008). Extracellular matrix of the central nervous system: From neglect to challenge. Histochemistry and Cell Biology,130(4), 635–653. doi:10.1007/s00418-008-0485-9.